Please login to the form below

Not currently logged in
Email:
Password:

Pharma news in brief

Our weekly round-up of news affecting the industry

Novartis ups Chiron bid
Novartis has raised its bid to buy out vaccine group Chiron, winning over two large investors who had previously been opposed to the deal. CAM North America and ValueAct, who control 17 per cent of the California-based company, have stated that they intend to vote in favour of the revised offer. Novartis, which already has a 44 per cent stake in Chiron, has offered $5.4bn ($48 a share) up from its September 2005 offer of $40 a share. Analysts said buying Chiron will give Novartis greater exposure to vaccines, an increasingly important market.

FTC study into branded generics
The US Federal Trade Commission is planning a study on the competitive effects of pharma companies' increasing use of `authorised generics', generic versions of their own drugs to stave off generic competitors. The move is a sign of the US government's concerns over the way firms seek to delay generic competition and end patent challenges by generics firms. The FTC has appealed to the US Supreme Court to hear a case it lost last year over the penalty it meted out to Schering-Plough for its settlement to delay a generic rival to one of its drugs.

Erbitux gets EU approval for head and neck cancer
The European Commission has granted marketing authorisation to Merck KGaA to extend the use of cancer drug Erbitux, in combination with radiotherapy, for the treatment of patients with head and neck cancer. The drug will be available for the new indication in all 25 European member states as well as Iceland and Norway. ìErbitux offers the potential for improved control and extended survival even in severe disease,î said Dr James Bonner, from the University of Alabama.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

Is China ready for a pharmaceutical gold rush?
Some describe doing business in China as akin to the 1990s internet boom – so how stable is its future?...
AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...

Infographics